We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+38.02%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.72B
AUM Growth
+$398M
Cap. Flow
+$23.1M
Cap. Flow %
1.34%
Top 10 Hldgs %
68.24%
Holding
45
New
–
Increased
23
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.6M
2
SAGE
Sage Therapeutics
SAGE
+$19.7M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
PRTA icon
Prothena Corp
PRTA
+$7.82M
5
UTHR icon
United Therapeutics
UTHR
+$5.38M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.9M
2
MDVN
MEDIVATION, INC.
MDVN
+$16.5M
3
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$15.8M
4
SQNM
SEQUENOM INC NEW
SQNM
+$9.43M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 94.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
26
DELISTED
Exact Sciences
EXAS
$7.37M 0.43%
396,976
+700
+0.2% +$12.3K
TLPH icon
27
Talphera
TLPH
$72.7M
$6.36M 0.37%
81,730
+10,458
+15% +$695K
AIMT
28
DELISTED
Aimmune Therapeutics
AIMT
$5.7M 0.33%
379,727
+54,128
+17% +$731K
VIRX
29
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.08M 0.3%
33,214
– –
ALIM
30
DELISTED
Alimera Sciences
ALIM
$4.49M 0.26%
200,920
– –
ALGN icon
31
Align Technology
ALGN
$12.4B
$3.51M 0.2%
37,457
+1,100
+3% +$99.5K
ACGN
32
DELISTED
Aceragen Inc
ACGN
$3.22M 0.19%
9,257
– –
DRNA
33
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.57M 0.09%
267,890
– –
OCGN icon
34
Ocugen
OCGN
$475M
$1.46M 0.08%
7,576
– –
PGEN icon
35
Precigen
PGEN
$2.45B
$1.32M 0.08%
47,524
– –
CYTK icon
36
Cytokinetics
CYTK
$10.5B
$1.14M 0.07%
123,686
– –
SPHS
37
DELISTED
Sophiris Bio, Inc.
SPHS
$768K 0.04%
247,000
-247,000
-50% -$929K
ARCT icon
38
Arcturus Therapeutics
ARCT
$216M
$674K 0.04%
38,970
– –
OREX
39
DELISTED
Orexigen Therapeutics, Inc.
OREX
$555K 0.03%
167,302
– –
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$337K 0.02%
29,500
– –
QURE icon
41
uniQure
QURE
$3.13B
$156K 0.01%
20,453
– –
MRNS
42
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$116K 0.01%
15,879
– –
SQNM
43
DELISTED
SEQUENOM INC NEW
SQNM
– –
-10,322,377
Closed -$9.43M
HTWR
44
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-272,986
Closed -$15.8M
MDVN
45
DELISTED
MEDIVATION, INC.
MDVN
– –
-273,983
Closed -$16.5M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q3 2016 Portfolio in Review

As of Q3 2016, Palo Alto Investors held 45 positions worth $1.72B, up 30% from $1.32B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Palo Alto Investors's Q3 2016 filing shows 23 increased, 5 reduced and 3 closed positions. The largest sale was Abiomed Inc, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q3 2016, an estimated $28.6M increase.
  • Palo Alto Investors's biggest Q3 2016 reduction was Abiomed Inc, cutting an estimated $21.9M.
  • Palo Alto Investors fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $16.5M.
  • Palo Alto Investors's ten largest holdings make up 68% of its $1.72B portfolio in Q3 2016.
  • Palo Alto Investors opened 0 new positions and closed 3 in Q3 2016.
  • Palo Alto Investors's portfolio value rose 30% quarter-over-quarter to $1.72B.

Based on Palo Alto Investors's 13F filing for Q3 2016, filed 14 Nov 2016.